{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:58:52Z","timestamp":1790488732866,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Anti-malarial resistance is a threat to recent gains in malaria control. This study aimed to assess the efficacy and safety of artesunate\u2013amodiaquine (ASAQ) and artemether\u2013lumefantrine (AL) in the management of uncomplicated malaria and to measure the prevalence of molecular markers of resistance of\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      in sentinel sites in Maferinyah and Lab\u00e9 Health Districts in Guinea in 2016.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a two-arm randomised controlled trial of the efficacy of AL and ASAQ among children aged 6\u201359\u00a0months with uncomplicated\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      malaria in two sites. Children were followed for 28\u00a0days to assess clinical and parasitological response. The primary outcome was the Kaplan\u2013Meier estimate of Day 28 (D28) efficacy after correction by microsatellite-genotyping. Pre-treatment (D0) and day of failure samples were assayed for molecular markers of resistance in the\n                      <jats:italic>pfk13<\/jats:italic>\n                      and\n                      <jats:italic>pfmdr1<\/jats:italic>\n                      genes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 421 participants were included with 211 participants in the Maferinyah site and 210 in Lab\u00e9. No early treatment failure was observed in any study arms. However, 22 (5.3%) participants developed a late treatment failure (8 in the ASAQ arm and 14 in the AL arm), which were further classified as 2 recrudescences and 20 reinfections. The Kaplan\u2013Meier estimate of the corrected efficacy at D28 was 100% for both AL and ASAQ in Maferinyah site and 99% (95% Confidence Interval: 97.2\u2013100%) for ASAQ and 99% (97.1\u2013100%) for AL in Lab\u00e9. The majority of successfully analysed D0 (98%, 380\/389) and all day of failure (100%, 22\/22) samples were wild type for\n                      <jats:italic>pfk13<\/jats:italic>\n                      . All 9 observed\n                      <jats:italic>pfk13<\/jats:italic>\n                      mutations were polymorphisms not associated with artemisinin resistance. The NFD haplotype was the predominant haplotype in both D0 (197\/362, 54%) and day of failure samples (11\/18, 61%) successfully analysed for\n                      <jats:italic>pfmdr1<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study observed high efficacy and safety of both ASAQ and AL in Guinea, providing evidence for their continued use to treat uncomplicated malaria. Continued monitoring of ACT efficacy and safety and molecular makers of resistance in Guinea is important to detect emergence of parasite resistance and to inform evidence-based malaria treatment policies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-020-03290-w","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T08:03:08Z","timestamp":1592985788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of artesunate\u2013amodiaquine and artemether\u2013lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4950-6224","authenticated-orcid":false,"given":"Abdoul Habib","family":"Beavogui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alioune","family":"Camara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Delamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Saliou","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye","family":"Doumbouya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karifa","family":"Kourouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Bouedouno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Guilavogui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaly","family":"dos Santos Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldin","family":"Talundzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aissata","family":"Fofana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz M.","family":"Plucinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"3290_CR1","unstructured":"WHO. World Malaria Report 2018. Geneva: World Health Organization; 2018. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/275867\/9789241565653-eng.pdf. Accessed 12 Jan 2020."},{"key":"3290_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nature24059","volume":"550","author":"RW Snow","year":"2017","unstructured":"Snow RW, Sartorius B, Kyalo D, Maina J, Amratia P, Mundia CW, et al. The prevalence of Plasmodium falciparum in sub Saharan Africa since 1900. Nature. 2017;550:515.","journal-title":"Nature"},{"key":"3290_CR3","unstructured":"WHO. Global Health Observation (GHO) data on malaria. Geneva: World Health Organization; 2018. https:\/\/www.who.int\/gho\/malaria\/en\/. Accessed 20 Jan 2019."},{"key":"3290_CR4","doi-asserted-by":"crossref","unstructured":"WHO. Guidelines for the treatment of malaria, 3rd edn. Geneva: World Health Organization; 2015. p. 15\u2013115. https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241549127\/en\/. Accessed 19 June 2019.","DOI":"10.1097\/01.NAJ.0000460670.72661.81"},{"key":"3290_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"3290_CR6","unstructured":"WHO. Global database on antimalarial drug efficacy and resistance. Geneva: World Health Organization; 2019. https:\/\/www.who.int\/malaria\/areas\/drug_resistance\/drug_efficacy_database\/en\/. Accessed 19 June 2019."},{"key":"3290_CR7","doi-asserted-by":"publisher","first-page":"e0222379","DOI":"10.1371\/journal.pone.0222379","volume":"14","author":"YL Ntamba","year":"2019","unstructured":"Ntamba YL, Mavoko HM, Kalabuanga M, Fungula B, Nsengi PMN, Lutete GT, et al. Safety and tolerability of artesunate\u2013amodiaquine, artemether\u2013lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo. PLoS ONE. 2019;14:e0222379.","journal-title":"PLoS ONE"},{"key":"3290_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12936-018-2524-x","volume":"17","author":"MA Kakolwa","year":"2018","unstructured":"Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in mainland Tanzania. Malar J. 2018;17:369.","journal-title":"Malar J."},{"key":"3290_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12936-018-2290-9","volume":"17","author":"E Davlantes","year":"2018","unstructured":"Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, F\u00e9lix J, et al. Efficacy and safety of artemether\u2013lumefantrine, artesunate\u2013amodiaquine, and dihydroartemisinin\u2013piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. Malar J. 2018;17:144.","journal-title":"Malar J."},{"key":"3290_CR10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/infdis\/jiv551","volume":"213","author":"A Yeka","year":"2016","unstructured":"Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, et al. Artesunate\/amodiaquine versus artemether\/lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial. J Infect Dis. 2016;213:1134\u201342.","journal-title":"J Infect Dis"},{"key":"3290_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-019-2730-1","volume":"18","author":"DS Ishengoma","year":"2019","unstructured":"Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, et al. Efficacy and safety of artemether\u2013lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18:88.","journal-title":"Malar J."},{"key":"3290_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1128\/AAC.04181-14","volume":"59","author":"MM Plucinski","year":"2015","unstructured":"Plucinski MM, Talundzic E, Morton L, Dimbu PR, Macaia AP, Fortes F, et al. Efficacy of artemether\u2013lumefantrine and dihydroartemisinin\u2013piperaquine for treatment of uncomplicated malaria in children in Zaire and U\u00edge Provinces, angola. Antimicrob Agents Chemother. 2015;59:437\u201343.","journal-title":"Antimicrob Agents Chemother"},{"key":"3290_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12936-016-1122-z","volume":"15","author":"C Fan\u00e7ony","year":"2016","unstructured":"Fan\u00e7ony C, Brito M, Gil JP. Plasmodium falciparum drug resistance in Angola. Malar J. 2016;15:74.","journal-title":"Malar J."},{"key":"3290_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12936-019-3015-4","volume":"18","author":"BR Adegbite","year":"2019","unstructured":"Adegbite BR, Edoa JR, Honkpehedji YJ, Zinsou FJ, Dejon-Agobe JC, Mbong-Ngwese M, et al. Monitoring of efficacy, tolerability and safety of artemether\u2013lumefantrine and artesunate\u2013amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambar\u00e9n\u00e9, Gabon: an open-label clinical trial. Malar J. 2019;18:424.","journal-title":"Malar J."},{"key":"3290_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-018-0259-3","volume":"19","author":"S Whegang Youdom","year":"2019","unstructured":"Whegang Youdom S, Chiabi A, Basco LK. Monitoring the efficacy and safety of artemisinin-based combination therapies: a review and network meta-analysis of antimalarial therapeutic efficacy trials in Cameroon. Drugs R D. 2019;19:1\u201314.","journal-title":"Drugs R D."},{"key":"3290_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1475-2875-6-54","volume":"6","author":"M Bonnet","year":"2007","unstructured":"Bonnet M, Roper C, F\u00e9lix M, Coulibaly L, Kankolongo GM, Guthmann JP. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine\u2013pyrimethamine in N\u2019Z\u00e9r\u00e9kor\u00e9. Malar J. 2007;6:54.","journal-title":"Malar J."},{"key":"3290_CR17","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","volume":"391","author":"I Sagara","year":"2018","unstructured":"Sagara I, Habib Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Pyronaridine\u2013artesunate or dihydroartemisinin\u2013piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial. Lancet. 2018;391:1378\u201390.","journal-title":"Lancet"},{"key":"3290_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12936-019-2664-7","volume":"18","author":"A Camara","year":"2019","unstructured":"Camara A, Moriarty LF, Guilavogui T, Diakit\u00e9 PS, Zoumanigui JS, Sidib\u00e9 S, et al. Prescriber practices and patient adherence to artemisinin-based combination therapy for the treatment of uncomplicated malaria in Guinea, 2016. Malar J. 2019;18:23.","journal-title":"Malar J."},{"key":"3290_CR19","unstructured":"Minist\u00e8re de la sant\u00e9 et l\u2019Hygi\u00e8ne Publique; Direction Nationale de la Pr\u00e9vention et de la Sant\u00e9. Programme national de lutte contre le paludisme; 2011;(Dlm):2003\u20135. https:\/\/www.invest.gov.gn\/document\/programme-national-de-lutte-contre-le-paludisme. Accessed 20 June 2019."},{"key":"3290_CR20","unstructured":"Institut National de la Statistique. Enqu\u00eate de prevalence parasitaire du paludisme et de l\u2019anemie- Guin\u00e9e 2016. Conakry, Guin\u00e9e; 2017. https:\/\/dhsprogram.com\/pubs\/pdf\/FR332\/FR332.pdf. Accessed 28 Mar 2019."},{"key":"3290_CR21","unstructured":"Minist\u00e8re de la Sant\u00e9, Programme National de Lutte contre le Paludisme. Plan strat\u00e9gique national de lutte contre le paludisme 2013\u20132017. Guinee; 2014 http:\/\/pnlp-guinee.org\/."},{"key":"3290_CR22","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44048\/9789241597531_eng.pdf?sequence=1. Accessed 6 Aug 2019."},{"key":"3290_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1017\/S0031182005008267","volume":"131","author":"SS Mahajan","year":"2005","unstructured":"Mahajan SS, Kamath VR, Ghatpande SS. Synergistic antimalarial activity of ketones with rufigallol and vitamin C. Parasitology. 2005;131:459.","journal-title":"Parasitology"},{"key":"3290_CR24","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jinorgbio.2007.01.006","volume":"101","author":"SM Chemaly","year":"2007","unstructured":"Chemaly SM, Chen CT, van Zyl RL. Naturally occurring cobalamins have antimalarial activity. J Inorg Biochem. 2007;101:764\u201373.","journal-title":"J Inorg Biochem"},{"key":"3290_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00508-005-0446-4","volume":"117","author":"D Samal","year":"2005","unstructured":"Samal D, Rojanawatsirivet C, Wernsdorfer G, Kollaritsch H, Sirichaisinthop J, Wernsdorfer WH. Synergism of desbutyl\u2013benflumetol and retinol against Plasmodium falciparum in vitro. Wien Klin Wochenschr. 2005;117:39\u201344.","journal-title":"Wien Klin Wochenschr"},{"key":"3290_CR26","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S0140-6736(02)08360-5","volume":"359","author":"L Serghides","year":"2002","unstructured":"Serghides L, Kain KC. Mechanism of protection induced by vitamin A in falciparum malaria. Lancet. 2002;359:1404\u20136.","journal-title":"Lancet"},{"key":"3290_CR27","first-page":"402","volume":"30","author":"VH Talib","year":"1982","unstructured":"Talib VH, Hasija BD, Diwan VM, Verma MC. A clinico-haematological profile of malaria. J Assoc Physicians India. 1982;30:402\u20134.","journal-title":"J Assoc Physicians India"},{"key":"3290_CR28","first-page":"120","volume":"6","author":"PS Ghalaut","year":"2016","unstructured":"Ghalaut PS, Atri K, Gaur N, Jain S, Chahal A, Pahuja I, et al. To study the clinical profile and etiological spectrum of patients with splenomegaly in a tertiary care centre of North India. Int J Sci Res Publ. 2016;6:120.","journal-title":"Int J Sci Res Publ."},{"key":"3290_CR29","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.1128\/AAC.00072-15","volume":"59","author":"MM Plucinski","year":"2015","unstructured":"Plucinski MM, Morton L, Bushman M, Dimbu PR, Udhayakumar V. Robust algorithm for systematic classification of malaria late treatment failures as recrudescence or reinfection using microsatellite genotyping. Antimicrob Agents Chemother. 2015;59:6096\u2013100.","journal-title":"Antimicrob Agents Chemother"},{"key":"3290_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12936-018-2233-5","volume":"17","author":"D Ljolje","year":"2018","unstructured":"Ljolje D, Dimbu PR, Kelley J, Goldman I, Nace D, Macaia A, et al. Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015. Malar J. 2018;17:84.","journal-title":"Malar J."},{"key":"3290_CR31","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.3201\/eid2313.170366","volume":"23","author":"ES Halsey","year":"2017","unstructured":"Halsey ES, Venkatesan M, Plucinski MM, Talundzic E, Lucchi NW, Zhou Z, et al. Capacity development through the US President\u2019s malaria initiative\u2013supported antimalarial resistance monitoring in Africa network. Emerg Infect Dis. 2017;23:S53\u20136.","journal-title":"Emerg Infect Dis"},{"key":"3290_CR32","doi-asserted-by":"publisher","first-page":"526","DOI":"10.4269\/ajtmh.16-0780","volume":"97","author":"R Mwaiswelo","year":"2017","unstructured":"Mwaiswelo R, Ngasala B, Gil JP, Malmberg M, Jovel I, Xu W, et al. Sustained high cure rate of artemether\u2013lumefantrine against uncomplicated Plasmodium falciparum malaria after 8\u00a0years of its wide-scale use in Bagamoyo District, Tanzania. Am J Trop Med Hyg. 2017;97:526\u201332.","journal-title":"Am J Trop Med Hyg."},{"key":"3290_CR33","doi-asserted-by":"publisher","first-page":"e0176004","DOI":"10.1371\/journal.pone.0176004","volume":"12","author":"M Teklemariam","year":"2017","unstructured":"Teklemariam M, Assefa A, Kassa M, Mohammed H, Mamo H. Therapeutic efficacy of artemether\u2013lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia. PLoS ONE. 2017;12:e0176004.","journal-title":"PLoS ONE"},{"key":"3290_CR34","unstructured":"Institut National de la Statistique (INS); Minist\u00e8re du Plan et du D\u00e9veloppement Economique. Enqu\u00eate D\u00e9mographique et de Sant\u00e9, EDS 2018. Conakry, Guinea; 2019. http:\/\/www.stat-guinee.org\/index.php\/publications-ins\/rapports-d-enquetes\/category\/86-enquetes-demographiques-et-de-sante-et-enquetes-mics?download=168:rapport-d-enquete-demographique-et-de-sante-2018. Accessed 30 Nov 2019."},{"key":"3290_CR35","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/S1473-3099(19)30261-0","volume":"19","author":"MD Conrad","year":"2019","unstructured":"Conrad MD, Rosenthal PJ. Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect Dis. 2019;19:e338\u201351.","journal-title":"Lancet Infect Dis."},{"key":"3290_CR36","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1086\/657120","volume":"51","author":"H Noedl","year":"2010","unstructured":"Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51:e82\u20139.","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"3290_CR37","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1475-2875-8-S1-S4","volume":"8","author":"A Djimd\u00e9","year":"2009","unstructured":"Djimd\u00e9 A, Lef\u00e8vre G. Understanding the pharmacokinetics of Coartem\u00ae. Malar J. 2009;8(Suppl. 1):S4.","journal-title":"Malar J."},{"key":"3290_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1368-7646(98)80208-2","volume":"1","author":"NJ White","year":"1998","unstructured":"White NJ. Preventing antimalarial drug resistance through combinations. Drug Resist Updat. 1998;1:3\u20139.","journal-title":"Drug Resist Updat."},{"key":"3290_CR39","first-page":"1352","volume":"211","author":"E Kamau","year":"2015","unstructured":"Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-saharan Africa. J Infect Dis. 2015;211:1352\u20135.","journal-title":"J Infect Dis"},{"key":"3290_CR40","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","volume":"374","author":"D M\u00e9nard","year":"2016","unstructured":"M\u00e9nard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453\u201364.","journal-title":"N Engl J Med"},{"key":"3290_CR41","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1186\/s12879-018-3453-6","volume":"18","author":"PI Mayengue","year":"2018","unstructured":"Mayengue PI, Niama RF, Kouhounina Batsimba D, Malonga-Massanga A, Louzolo I, Loukabou Bongolo NC, et al. No polymorphisms in K13-propeller gene associated with artemisinin resistance in Plasmodium falciparum isolated from Brazzaville, Republic of Congo. BMC Infect Dis. 2018;18:538.","journal-title":"BMC Infect Dis."},{"key":"3290_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1051\/parasite\/2016028","volume":"23","author":"A Ogouy\u00e8mi-Hounto","year":"2016","unstructured":"Ogouy\u00e8mi-Hounto A, Damien G, Deme AB, Ndam NT, Assohou C, Tchonlin D, et al. Lack of artemisinin resistance in Plasmodium falciparum in northwest Benin after 10\u00a0years of use of artemisinin-based combination therapy. Parasite. 2016;23:28.","journal-title":"Parasite."},{"key":"3290_CR43","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/infdis\/jiu491","volume":"211","author":"S Takala-Harrison","year":"2015","unstructured":"Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis. 2015;211:670\u20139.","journal-title":"J Infect Dis"},{"key":"3290_CR44","doi-asserted-by":"publisher","first-page":"e1004789","DOI":"10.1371\/journal.ppat.1004789","volume":"11","author":"E Talundzic","year":"2015","unstructured":"Talundzic E, Okoth SA, Congpuong K, Plucinski MM, Morton L, Goldman IF, et al. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog. 2015;11:e1004789.","journal-title":"PLoS Pathog"},{"key":"3290_CR45","unstructured":"WHO. Status report on artemisinin and ACT resistance. Geneva: World Health Organization; 2017. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255213\/WHO-HTM-GMP-2017.9-eng.pdf%3Bjsessionid%3DC776905C7E5F82DA454900D72C402ADE%3Fsequence%3D1. Accessed 14 Aug 2019."},{"key":"3290_CR46","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12936-016-1503-3","volume":"15","author":"SD Otienoburu","year":"2016","unstructured":"Otienoburu SD, Ma\u00efga-Ascofar\u00e9 O, Schramm B, Jullien V, Jones JJ, Zolia YM, et al. Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate\u2013amodiaquine fixed dose combination or artemether\u2013lumefantrine in Liberia. Malar J. 2016;15:452.","journal-title":"Malar J."},{"key":"3290_CR47","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1128\/AAC.00968-08","volume":"53","author":"CT Happi","year":"2009","unstructured":"Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O\u2019Neil M, et al. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether\u2013lumefantrine in nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2009;53:888\u201395.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03290-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-020-03290-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03290-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T19:43:58Z","timestamp":1624477438000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03290-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3290"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03290-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.21808\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.21808\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.21808\/v2","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"21 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for this study was obtained from the Guinean Ethics Committee for Health Research (Protocol Number: 43\/CNERS\/15) and the Office of the Associate Director for Science in the Centre for Global Health at the U.S. Centers for Disease Control and Prevention (Protocol Number: 2016-046). For each patient, signed informed consent was obtained from the parent\/guardian before inclusion, and in the presence of a witness in the case of an illiterate parent\/guardian. Data confidentiality was ensured by anonymizing patient information before analysis, keeping the patient forms in a locked cupboard and the electronic database on a password-protected computer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}